How have CTNM shares performed in 2024?

Contineum Therapeutics' stock was trading at $15.40 at the beginning of the year. Since then, CTNM stock has increased by 3.9% and is now trading at $16.00. View the best growth stocks for 2024 here .

When did Contineum Therapeutics IPO?

Contineum Therapeutics (CTNM) raised $110 million in an IPO on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00 per share.

When does the company's quiet period expire?

Contineum Therapeutics' quiet period expires on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its IPO on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Contineum Therapeutics?

Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CTNM

Contineum Therapeutics (CTNM) Stock Price, News & Analysis

→ Charles Payne’s Gift to Stock Investors (From Unstoppable Prosperity) (Ad)

Free CTNM Stock Alerts

$15.95

-0.05 (-0.31%)

(As of 10:44 AM ET)

Compare

Today's Range: $15.55
▼
$16.00
50-Day Range: N/A
52-Week Range: $13.90
▼
$16.05

Volume: 12,128 shs
Average Volume: 83,729 shs
Market Capitalization: $291.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Competitors Financials SEC Filings Social Media

Get Contineum Therapeutics alerts:

Ad Unstoppable Prosperity

Charles Payne’s Gift to Stock Investors

Right now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.

Watch Insider's Advantage Event Tuesday at 4:00 PM ET

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

CTNM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTNM Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive CTNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CTNM
CUSIP: N/A
CIK: 1855175
Web: www.contineum-tx.com
Phone: (858) 333-5280
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 18,260,000
Free Float: N/A
Market Cap: $291.61 million
Optionable: N/A
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Carmine N. Stengone MBA (Age 48)
MS, President, CEO, Secretary & Director
Comp: $790.3k
Mr. Peter T. Slover CPA (Age 49)
Chief Financial Officer
Comp: $569.7k
Dr. Daniel S. Lorrain Ph.D. (Age 55)
Chief Science Officer
Comp: $565.02k
Dr. Stephen L. Huhn F.A.A.P (Age 63)
F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development
Mr. Austin Chen Ph.D.
SVP & Head of Research
Mr. Michael Mayberry
Senior Director & Corporate Controller

Key Competitors

View All Competitors

CTNM Stock Analysis - Frequently Asked Questions

How have CTNM shares performed in 2024?: Contineum Therapeutics' stock was trading at $15.40 at the beginning of the year. Since then, CTNM stock has increased by 3.9% and is now trading at $16.00.
View the best growth stocks for 2024 here.
When did Contineum Therapeutics IPO?: Contineum Therapeutics (CTNM) raised $110 million in an IPO on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00 per share.
When does the company's quiet period expire?: Contineum Therapeutics' quiet period expires on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its IPO on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
How do I buy shares of Contineum Therapeutics?: Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTNM) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial